Biotech M&A Tracker 2026

A sponsor-led specialty-pharma take-private rather than a pipeline biotech takeout, but too large to ignore. The deal shows that private capital remains willing to underwrite scaled commercial biopharma assets with rare-disease exposure, even where the strategic logic is portfolio durability, operating control, and delisting rather than single-asset R&D upside.

A smaller and higher-risk public-acquirer / private-target transaction, but relevant as a recapitalization-style oncology platform deal. Liminatus is using stock to pivot toward CAR-T optionality despite limited cash, showing how distressed or microcap biotechs may use M&A to rebuild pipeline narratives when conventional financing remains constrained.

A platform tuck-in that extends Lilly's genetic-medicine toolkit rather than adding a near-term clinical asset. The read-through is that delivery remains a strategic bottleneck: large pharmas are willing to buy enabling technologies that could improve potency, tolerability, redosing, or tissue localization across broader genetic-medicine portfolios.

Angelini is using M&A to enter the U.S. market and scale its brain-health / rare-disease presence around a commercial neuromuscular platform. The read-through is that commercial rare-disease assets with concentrated specialist infrastructure remain strategic — particularly for ex-U.S. buyers seeking a U.S. beachhead rather than building one organically.

Not a therapeutic pipeline takeout — a high-signal biopharma-enabling infrastructure deal. Roche is folding PathAI into its Diagnostics division to deepen digital pathology and AI-enabled companion diagnostics, reinforcing that strategic M&A is increasingly extending from drugs into the data and diagnostic rails that shape precision-medicine adoption.

Strategically notable because Pathos is positioning it as an AI-sourced clinical oncology acquisition. The read-through is that AI-native developers are starting to use proprietary asset-screening platforms not just to design programs internally, but to identify and buy clinical-stage assets with differentiated early data.

Bayer is adding a clinical-stage ophthalmology asset and mechanism that could broaden its eye-care pipeline beyond existing retinal franchises. Ophthalmology remains a live M&A lane when the target offers a differentiated biology angle and a plausible path into large, high-burden diseases such as glaucoma and diabetic retinopathy.

UCB is doubling down on immunology with a platform-style acquisition built around T-cell engagers for autoimmune disease. The deal reinforces the broader sector push toward immune reset approaches, where oncology-derived modalities are being repurposed for chronic autoimmune indications with potentially deeper and more durable efficacy.

A public-to-private commercial-stage cardiovascular takeout rather than a classic discovery-platform deal. The read-through is that financial sponsors are prepared to underwrite commercial execution where public markets have struggled to price specialty-pharma assets — especially with an approved product base and clearer operating levers outside the public-company spotlight.

Chiesi is buying a near-commercial rare-disease asset that could change the HAE treatment paradigm by moving on-demand therapy toward an oral option. Strategics will pay meaningful premiums for late-stage / launch-ready rare-disease assets where convenience can drive differentiation and the buyer can plug the product into an existing rare-disease infrastructure.

Teva is adding an NDA-ready neuroscience asset that fits its pivot toward branded growth and specialty neurology. Buyers are willing to pay for late-stage CNS assets when the regulatory path is close and the product can slot into an existing commercial footprint — even in indications that historically have seen limited therapeutic innovation.

Shows consolidation in royalty aggregation. The read-through is that royalty portfolios remain attractive strategic assets when acquirers can combine diversified cash-flow streams, lower public-company costs, and create scale in non-dilutive biopharma financing infrastructure.

Lilly is again using private-company M&A to deepen oncology / hematology exposure, this time around a potentially differentiated JAK2 profile in MPNs. Strategic appetite remains strong for targeted hematology assets when the mechanism is validated but the product profile could still improve on tolerability, selectivity, or depth of response.

The largest disclosed 2026 biopharma M&A deal on the tracker — more about commercial scale than single-asset R&D risk. Sun Pharma is using M&A to add a global branded portfolio, women's-health infrastructure, and biosimilar exposure, reinforcing that strategics will pay up for durable commercial platforms when growth, geographic reach, and portfolio breadth are immediately accretive.

A scale-and-integration deal: Amneal is buying Kashiv to turn an existing biosimilar partnership into a fully integrated global platform. Biosimilars are becoming an M&A lane in their own right as companies position for the next biologics LOE wave and try to control development, manufacturing, and commercial economics under one roof.

Lilly is making another major platform bet to expand beyond obesity and deepen its oncology footprint, this time around in vivo CAR-T. Strategically, the deal signals real appetite for approaches that could simplify cell-therapy logistics and potentially widen access if in vivo delivery proves clinically durable.

UCB is using M&A to push beyond conventional epilepsy pharmacology and establish a position in advanced regenerative therapies. Large-cap CNS buyers are increasingly willing to underwrite platform and modality risk when it could produce disease-modifying benefit in entrenched, high-burden neurological conditions.

Another sign that Lilly is actively building oncology depth through targeted tuck-ins rather than waiting only for large public takeouts. The strategic logic is platform-driven: dual-payload ADCs could offer a path to more durable responses and better resistance management in solid tumors.

Gilead is expanding beyond cell therapy and immunology into a deeper ADC capability set — buying not just a clinical ovarian-cancer asset but differentiated linker-payload and conjugation technology. Buyers are still willing to pay heavily for clinically anchored oncology platforms when they can strengthen a broader franchise rather than add a single isolated asset.

Neurocrine is buying a newly launched, already de-risked rare-disease product and using M&A to extend beyond neuroscience into endocrinology / metabolic disease. Buyers are still willing to pay meaningful control premiums for approved assets with visible commercial traction, especially where the target opens a new franchise lane rather than just adding pipeline optionality.

Biogen is buying immediate commercial revenue plus a broader complement platform at a time when it needs new growth vectors beyond legacy MS. The deal adds approved rare-disease and retinal assets today while giving Biogen a more credible foothold in nephrology ahead of its broader immunology build-out.

Lilly is paying up to secure a clinically de-risking orexin agonist platform and enter sleep medicine with a potential best-in-class wakefulness asset. Large-cap buyers are willing to underwrite differentiated neuroscience mechanisms when there is clear biology, sizable commercial white space, and room to build a broader franchise around the lead program.

Otsuka is making a meaningful bet on the next wave of neuropsychiatry by buying a company built around rapid-acting, psychedelic-adjacent medicines. Large buyers are willing to underwrite differentiated CNS mechanisms where the clinical need is large and the commercial white space remains open.

Novartis is doubling down on allergy with a differentiated anti-IgE asset that could help defend and extend the franchise around proven IgE biology as Xolair matures. The key strategic question is whether Exl-111 can offer a meaningfully better efficacy / convenience profile and become the next-generation backbone in food allergy and adjacent IgE-driven settings.

Merck is paying up for a late-enough oncology asset with a plausible commercial lane in CML as it works to deepen its post-Keytruda pipeline. Strategic buyers still want differentiated hematology / onco assets, especially where there is a credible best-in-class argument.

Gilead is leaning harder into autoimmune disease with an "immune reset" style asset that could broaden its inflammation franchise beyond its historical core — and adds another meaningful strategic use of capital soon after the Arcellx deal.

Servier is buying a commercial rare-oncology platform rather than just a development story, pairing pediatric low-grade glioma with its existing neuro-oncology footprint and paying a clear control premium for an already de-risked asset base.

Not a classic venture-biotech platform buyout: Esperion is using M&A to add a commercial cardiovascular product and broaden its franchise beyond cholesterol-lowering.

GSK is paying a meaningful sum for a private clinical-stage cardiopulmonary asset that could strengthen its respiratory and inflammation franchise — placing it into an increasingly important pulmonary hypertension strategic lane.

Gilead buys out its partner to take full control and economics of anito-cel ahead of a potential launch — accelerating development and commercialisation while eliminating the existing profit-share, milestones, and royalties.

More merger-like than a classic cash buyout — but still a control transaction that recapitalizes a struggling public biotech around a new oncology asset base and fresh private financing.

Lilly's entry into in vivo CAR-T — aiming to turn cell therapy from a bespoke, ex vivo manufacturing model into something more scalable and potentially usable across broader autoimmune indications.

Broadens Halozyme's delivery stack beyond ENHANZE, adding a differentiated formulation capability that could expand the set of biologics feasible for at-home SC dosing and support additional partnering / royalty pathways.

Bolt-on to deepen GSK's immunology pipeline with a clinically validated target and a potential longer-dosing-interval anti-IgE profile.

Adds a clinical-stage oral inflammation pipeline — notably NLRP3 and IBD mechanisms — to extend Lilly's immunology footprint beyond incretins.

Expands Amgen oncology pipeline with a first-in-class targeted protein degradation approach in AML — a high unmet-need setting.